Search Results | MSF Science Portal

Journal Article

|

Research

Sweeney S, Laurence YV, Berry C, Singh MP, Dodd M, et al.

2025-02-01 • Lancet Global Health

BACKGROUND

New 6-month rifampicin-resistant tuberculosis treatment regimens containing bedaquiline, pretomanid, and linezolid (BPaL) with or without moxifloxaci...

Journal Article

|

Research

Pelzer PT, Stuck L, Martinez L, Richards AS, Acuña-Villaorduña C, et al.

2024-12-19 • Lancet Microbe

BACKGROUND

Tuberculosis vaccine trials using disease as the primary endpoint are large, time consuming, and expensive. An earlier immunological measure of the p...

Journal Article

|

Research

Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, et al.

2024-02-01 • Lancet Respiratory Medicine

BACKGROUND
Around 500,000 people worldwide develop rifampicin-resistant tuberculosis each year. The proportion of successful treatment outcomes remains low and new treatments are nee...

Journal Article

|

Research

Bonnet MMB, Vasiliu A, Tchounga BK, Cuer B, Fielding K, et al.

2023-10-30 • Lancet Global Health

BACKGROUND
Globally, the uptake of tuberculosis-preventive treatment (TPT) among children with household tuberculosis contact remains low, partly due to the necessity of bringing chi...

Journal Article

|

Research

Jindani A, Atwine D, Grint D, Bah B, Adams J, et al.

2023-09-01 • NEJM Evidence

BACKGROUND
Shorter but effective tuberculosis treatment regimens would be of value to the tuberculosis treatment community. High-dose rifampicin has been associated with more rapid a...

Conference Material

|

Slide Presentation

Stringer B, Lowton K, Cusinato M, Fielding K, Liverko I, et al.

2023-06-07 • MSF Scientific Day International 2023

Conference Material

|

Poster

Motta I, Cusinato M, Ludman A, Abdrasuliev T, Butabekov I, et al.

2023-06-07 • MSF Scientific Day International 2023

Conference Material

|

Abstract

Stringer B, Lowton K, Cusinato M, Fielding K, Liverko I, et al.

2023-06-07 • MSF Scientific Day International 2023

INTRODUCTION
The TB-PRACTECAL study trialed a shorter, more tolerable regimen of oral drugs than standard of care (SoC) – which can last for up to 20 months and involve both injectab...

Journal Article

|

Research

Broger T, Koeppel L, Huerga H, Miller P, Gupta-Wright A, et al.

2023-06-01 • Lancet Global Health

BACKGROUND
Sputum is the most widely used sample to diagnose active tuberculosis, but many people living with HIV are unable to produce sputum. Urine, in contrast, is readily availab...

Journal Article

|

Research

Sweeney S, Berry C, Kazounis E, Motta I, Vassall A, et al.

2022-12-07 • PLOS Global Public Health

Current options for treating tuberculosis (TB) that is resistant to rifampicin (RR-TB) are few, and regimens are often long and poorly tolerated. Following recent evidence from the TB-PR...

Journal Article

|

Pre-Print

Sweeney S, Berry C, Kazounis E, Motta I, Vassall A, et al.

2022-11-10 • medRxiv

INTRODUCTION
Current options for treating tuberculosis (TB) that is resistant to rifampicin (RR-TB) are few, and regimens are often long and poorly tolerated. Following recent eviden...

Journal Article

|

Research

Gupta-Wright A, Corbett EL, Wilson D, van Oosterhout JJ, Dheda K, et al.

2019-04-05 • PLOS Medicine

The prevalence of and mortality from HIV-associated tuberculosis (HIV/TB) in hospital inpatients in Africa remains unacceptably high. Currently, there is a lack of tools to identify thos...

Journal Article

|

Research

Rangaka MX, Wilkinson RJ, Boulle AM, Glynn JR, Fielding K, et al.

2014-05-14 • Lancet

Antiretroviral therapy reduces the risk of tuberculosis, but tuberculosis is more common in people with HIV than in people without HIV. We aimed to assess the effect of isoniazid prevent...

Conference Material

|

Video

Berry C, Motta I, Kazounis E, Fielding K, Dodd M, et al.

2022-06-07 • MSF Scientific Days International 2022

No abstract available.

Conference Material

|

Slide Presentation

Berry C, Motta I, Kazounis E, Fielding K, Dodd M, et al.

2022-05-11 • MSF Scientific Days International 2022

Journal Article

|

Research

Furin J, Alirol E, Allen E, Fielding K, Merle CS, et al.

2016-03-01 • International Journal of Tuberculosis and Lung Disease

Drug-resistant tuberculosis (DR-TB) is a growing public health problem, and for the first time in decades, new drugs for the treatment of this disease have been developed. These new dru...

Journal Article

|

Research

Berry C, du Cros PAK, Fielding K, Gajewski S, Kazounis E, et al.

2022-06-13 • Trials

BACKGROUND
Globally rifampicin-resistant tuberculosis disease affects around 460,000 people each year. Currently recommended regimens are 9-24 months duration, have poor efficacy and...

Conference Material

|

Abstract

Berry C, Motta I, Kazounis E, Fielding K, Dodd M, et al.

2022-05-11 • MSF Scientific Days International 2022

INTRODUCTION
Rifamipcin-resistant tuberculosis (RR-TB) affects around 465,000 people each year globally. Current treatment is of 9-20 months’ duration; is toxic and poorly efficaciou...

Journal Article

|

Commentary

Nyang'wa BT, Berry C, Fielding K, Nunn AJ

2019-07-27 • Lancet

Journal Article

|

Research

Dhana A, Hamada Y, Kengne AP, Kerkhoff AD, Broger T, et al.

2022-05-16 • Journal of Infection

BACKGROUND
WHO recommends urine lateral-flow lipoarabinomannan (LF-LAM) testing with AlereLAM in HIV-positive inpatients only if screening criteria are met. We assessed the performan...

Science Portal

24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation

Effectiveness of the primary Bacillus Calmette-Guérin vaccine against the risk of Mycobacterium tuberculosis infection and tuberculosis disease: a meta-analysis of individual participant data

Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial

Effectiveness of a community-based approach for the investigation and management of children with household tuberculosis contact in Cameroon and Uganda: a cluster-randomised trial

Four-month high-dose rifampicin regimens for pulmonary tuberculosis

Patient-reported experiences and quality of life outcomes in the TB-PRACTECAL clinical trial (PRACTECAL-PRO): a mixed-methods, multi-site study

ECG findings in BPaL-based TB treatment regimens: the geographical effect on QT prolongation

Patient-reported experiences and quality of life outcomes in the TB-PRACTECAL clinical trial: PRACTECAL-PRO

Diagnostic yield of urine lipoarabinomannan and sputum tuberculosis tests in people living with HIV: a systematic review and meta-analysis of individual participant data

Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis

Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis

Risk score for predicting mortality including urine lipoarabinomannan detection in hospital inpatients with HIV-associated tuberculosis in sub-Saharan Africa: Derivation and external validation cohort study

Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial

24-week regimens for treatment of rifampicin-resistant tuberculosis: four-arm randomised trial

24-week regimens for treatment of rifampicin-resistant tuberculosis: four-arm randomised trial

Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults

TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II–III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis

24-week regimens for treatment of rifampicin-resistant tuberculosis: four-arm randomised trial

Multidrug-resistant tuberculosis

Diagnostic accuracy of WHO screening criteria to guide lateral-flow lipoarabinomannan testing among HIV-positive inpatients: a systematic review and individual participant data meta-analysis